Latest news

Latest publications

  • Hillion S, Miranda A, Le Dantec C, Boudigou M, Le Pottier L, Cornec D, Torres R & Pelanda R. Maf expression in B cells restricts reactive plasmablast and germinal center B cell expansion. Nat Commun 15, 7982 (2024). DOI: 10.1038/s41467-024-52224-6

     

  • Zimmermann F, Robin F, Diot E, Bleuzen A, Jousse-Joulin S, de Moreuil C, Belhomme N, Cazalets C, Garlantézec R, Gazzola A, Llamas-Gutierrez F, Muraz R, Perlat A, Coiffier G, Lescoat A. Whole phenotype of patients with systemic sclerosis and sicca manifestations: Comparison with sicca manifestations from other causes. Semin Arthritis Rheum. 2024 Oct;68:152480. doi: 10.1016/j.semarthrit.2024.152480

     

  • Kedra J, Dieudé P, Giboin C, Marotte H, &al. Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission. Arthritis Rheumatol. 2024 Apr;76(4):541-552. doi: 10.1002/art.42752

     

  • Inanc N, Jousse-Joulin S, Abacar K, Cimşit Ç, Cimşit C, D'Agostino MA, Naredo E, Hocevar A, Finzel S, Pineda C, Keen H, Iagnocco A, Hanova P, Schmidt WA, Mumcu G, Terslev L, Bruyn GA. The Novel OMERACT Ultrasound Scoring System for Salivary Gland Changes in Patients With Sjögren Syndrome Is Associated With MRI and Salivary Flow Rates. J Rheumatol. 2024 Mar 1;51(3):263-269. doi: 10.3899/jrheum.2023-0202.

     

  • Gandolfo S, Bombardieri M, Pers JO, Mariette X, Ciccia F. Precision medicine in Sjögren’s disease. Lancet Rheumatol. 2024 May 6;S2665-9913(24)00039–0. PMID: 38723653

The UMR1227 'B Lymphocytes and Autoimmunity' brings together several clinical entities around the immunology laboratory.

Rheumatology, haematology, nephorology and odontology for a scientific project articulated around two main complementary and interconnected axes: an axis dedicated to the understanding of the mechanisms that govern the functional orientation of B cells in autoimmunity, and a translational axis aiming at developing new tools to improve the efficiency of B-cell targeting immunotherapies, while working on a better stratification of patients, a better understanding of the mode of action of these therapies, and the development of these therapies and innovative therapeutic strategies.

They support us

logo-inserm
logo_chu

 

 

logo_region_bretagne